MétaCan
Menu
Back to cohort

Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O<sub>2</sub>), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study

2004· article· en· W2256373696 on OpenAlexaff
John H. Suh, Baldassarre Stea, Abdenour Nabid, John J. Kresl, A. Fortin, J. P. Mercier, Neil Senzer, Eric L. Chang, Josefin-Beate Holz, Edward Shaw

Bibliographic record

VenueJournal of Clinical Oncology · 2004
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsUniversité de Sherbrooke
Fundersnot available
KeywordsMedicineClinical endpointHazard ratioRadiation therapyInternal medicineBrain metastasisPopulationBreast cancerCancerRandomized controlled trialSurgeryOncologyUrologyMetastasisConfidence interval

Abstract

fetched live from OpenAlex

1534 Background: Brain metastases represent a common cause of morbidity and mortality among cancer pts. The effectiveness of WBRT as primary therapy for brain metastases is limited by tissue hypoxia, which has been shown to cause radioresistance in solid tumors. RSR13 (efaproxiral) is a novel radiation sensitizer that acts as an allosteric modifier of hemoglobin, facilitates O2 release and decreases tissue hypoxia. Methods: A randomized, open-label Phase 3 study was conducted comparing RSR13 and WBRT to WBRT alone in pts. with newly diagnosed brain metastases from various solid tumors. In the RSR13 arm (n=271), pts. received RSR13 (75–100 mg/kg/d, IV) plus O2 followed by WBRT (30 Gy, 3 Gy/d x 10 days). In the Control arm (n=267), pts. received WBRT plus O2. The primary endpoint was survival. Secondary endpoints were RR in the brain, TTP, cause of death and QoL. Results: A total of 538 pts. were enrolled over 29 months at 82 sites in 12 countries. In the overall study population (n=538), the RSR13 arm demonstrated a 17.6% improvement in median survival time (MST) over the Control arm (5.26 mo vs. 4.47 mo; p=0.17). The survival benefit for RSR13 was statistically significant in a Cox multiple regression model (Hazard Ratio 0.78 [95% CI 0.64, 0.94], p=0.010). Pts. with breast cancer or NSCLC (n=414) receiving RSR13 had a 32.4% increase in MST vs. Control (5.91 vs. 4.47 mo; p=0.12). In pts. with breast cancer (n=115) the MST almost doubled in those who received RSR13 vs. Control (8.67 vs. 4.57 mo; p=0.006). The percentage of breast cancer pts. with stable/improved KPS at 3 months was significantly higher in the RSR13 arm (35% vs 18%, p=0.001). Related SAEs that are part of the RSR13 safety profile occurred in 7% of pts. The most common RSR13-related SAE was hypoxemia (3.4 %), which is dose-dependent and effectively managed with increased supplemental O2. Conclusions: The addition of RSR13 to WBRT was well tolerated and led to a 22% reduction in the risk of death for all pts. A near doubling in MST and significant improvement in QoL were observed in pts. with brain metastases from breast cancer. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Allos Therapeutics, Inc. Allos Therapeutics Allos Therapeutics, Inc. Allos Therapeutics

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.106
Threshold uncertainty score0.650

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0100.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0030.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.387
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicBrain Metastases and TreatmentFrench-language works237,207